Clal Biotechnology | CBI - Equity Capital And Reserves


Clal Biotechnology reported ILS121.41M in Equity Capital and Reserves for its fiscal quarter ending in December of 2023.





Equity Capital And Reserves Change Date
Arca Biopharma USD 469M 17.79M Dec/2025
aTyr Pharma USD -24.12M 104.35M Dec/2025
Bio Path USD -8M 846K Sep/2025
Brainstorm Cell Therapeutics USD -7.69M 1.64M Sep/2025
Cara Therapeutics USD 32.93M 41M Jun/2025
Clal Biotechnology ILS 121.41M 4.62M Dec/2023
Compugen USD 102.73M 58.9M Dec/2025
Immunic USD 10.5M 23.41M Sep/2025
Infinity Pharmaceuticals USD -37.41M 9.08M Jun/2023
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
RedHill Biopharma USD -4.41M 271K Jun/2025
TherapeuticsMD USD 27.67M 990K Jun/2024